Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 19, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	10,537	$9.49	1,109,638
Dec 12, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	9,154	$273.06	1,106,840
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	38,267	$263.22	1,106,795
Dec 12, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	228	$273.06	1,106,612
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	400	$264.21	1,106,395
Feb 12, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	30,858	$319.44	1,106,334
Dec 19, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	17,182	$11.64	1,099,101
Feb 12, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	17,274	$320.48	1,089,060
Dec 19, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	4,921	$20.32	1,081,919
Feb 12, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	8,021	$321.48	1,081,039

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media